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Ketamine is commonly used for procedural sedation and analgesia (PSA) in children. Evidence suggests it can be administered intranasally (IN). We sought to review the evidence
for IN ketamine for PSA in children.

Methods
We performed a systematic review of randomized trials of IN ketamine in PSA that reported
any sedation-related outcome in children 0 to 19 years. Trials were identified through electronic searches of MEDLINE (1946–2016), EMBASE (1947–2016), Google Scholar (2016),
CINAHL (1981–2016), The Cochrane Library (2016), Web of Science (2016), Scopus
(2016), clinical trial registries, and conference proceedings (2000–2016) without language
restrictions. The methodological qualities of studies and the overall quality of evidence were
evaluated using the Cochrane Collaboration’s Risk of Bias tool, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, respectively.

Results

Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.

The review included 7 studies (n = 264) of children ranging from 0 to 14 years. Heterogeneity in study design precluded meta-analysis. Most studies were associated with a low or
unclear risk of bias and outcome-specific ratings for quality of evidence were low or very
low. In four of seven studies, IN ketamine provided superior sedation to comparators and
resulted in adequate sedation for 148/175 (85%) of participants. Vomiting was the most
common adverse effect; reported by 9/91 (10%) of participants.

Funding: The author(s) received no specific
funding for this work.

Conclusions

Competing interests: The authors have declared
that no competing interests exist.

IN ketamine administration is well tolerated and without serious adverse effects. Although
most participants were deemed adequately sedated with IN ketamine, effectiveness of

PLOS ONE | https://doi.org/10.1371/journal.pone.0173253 March 20, 2017

1 / 15

Intranasal ketamine for procedural sedation and analgesia in children

sedation with respect to superiority over comparators was inconsistent, precluding a recommendation for PSA in children.

Introduction
A decade of dedicated “Pain Control and Research” [1] has failed to improve the pain management of children [2] and a 2011 survey found that less than one third receive analgesia for a
painful procedure [3]. Optimal pain management for children is advocated by the World
Health Organization [4] and the American Academy of Pediatrics [5]. Peripheral intravenous
(IV) insertion is one of the most common sources of pain in hospitalized children [6] and is
consistently associated with distress [7–10]. Procedural sedation and analgesia (PSA) for
maneuvers such as fracture reduction and laceration repair are common indications for IV
insertion in children. The demand for PSA in children outside the operating room is increasing at a rate of 10% annually [11]. Fifteen to 27% of ED physicians report performing a fracture
reduction every shift or every other shift, respectively [12], with ketamine being the most commonly used agent for PSA in children [12]. Therefore, a pain-free alternative to IV insertion is
an important goal for clinicians providing sedation to children.
As a possible alternative to IVs, intranasal (IN) drugs have become increasingly popular
because of ease of administration, minimal distress [3], a reduced risk of needle-stick injuries,
and fewer staffing and vascular access skill requirements [13]. Demonstrating the effectiveness
of IN ketamine for PSA may have widespread applicability in patients with needle-phobia, difficult IV access, in resource-limited settings, or when experience placing an IV is limited. IN
ketamine has gained recent popularity for laceration repair [14] and analgesia [15] and has
demonstrated good hemodynamic stability [16]. To date, no large trial or review exists upon
which to base broader adoption of PSA. If we are unable to generate a meaningful summary
measure of sedation supporting the use of IN ketamine, this review will highlight important
features to inform future clinical trials.
Our objectives were to summarize the evidence evaluating IN ketamine versus any comparator for children who require PSA with respect to effectiveness of sedation and analgesia, ease
of administration, and adverse effects. Our work has highlighted important strategies for the
conduct of future clinical trials of this non-invasive approach to PSA in children.

Material and methods
This review was conducted and reported in accordance with the Preferred Reporting Items for
Systematic Review and Meta-Analysis (PRISMA) guidelines [17] (See S1 Text). The review is
registered on PROSPERO (registry number CRD 420150299750) (See S2 Text).

Search strategy
A medical librarian (SH) developed the following search strategy (see S3 Text): Ovid MEDLINE (January 1946 to August 2016); Ovid EMBASE (January 1980 to August 2016); Web of
Science (August 2016); Scopus (2016); CINAHL (January 1981 to August 2016); Google
Scholar (2016); Cochrane Library (August 2016). For unpublished trials, we searched clinical
trial registries, research registries, and industry research databases. Key journals and conference proceedings were hand-searched from 2000 to 2016. We contacted authors for further
information and checked reference lists of all included trials. The original search was completed in December 2015 and repeated in August 2016. There were no language restrictions.

PLOS ONE | https://doi.org/10.1371/journal.pone.0173253 March 20, 2017

2 / 15

Intranasal ketamine for procedural sedation and analgesia in children

Study selection
We included all published and unpublished randomized and quasi-randomized trials comparing IN ketamine (alone or in combination) to any agent for children 0 to 19 years undergoing
PSA that reported any sedation-related outcome including at least one of: duration, onset,
depth, adequacy of sedation to facilitate the procedure, or adverse effects. Studies of both adult
and pediatric participants were included if the authors were able to provide pediatric-specific
data. We excluded sub-studies and secondary analyses of previously reported trials, studies of
ketamine for psychiatric disorders, studies of IN ketamine for anesthetic premedication, and
sub-dissociative dose ketamine. Two authors (NP and KC) independently screened titles and
abstracts using a standardized tool. We obtained full-text copies of all studies that were not
unanimously excluded and reviewed them to identify those suitable for inclusion. We resolved
disagreements or uncertainty by discussion and if necessary, through arbitration with a third
author (GJ).

Data extraction and methodological quality
Two review authors (NP and KC) independently extracted the following data using a studyspecific data extraction form. Data collected included age, dose, comparators, ease of administration, analgesia, adverse effects, additional sedation, proportion with adequate sedation,
depth, onset, and duration of sedation. We resolved disagreements or uncertainty by consensus and if necessary, through arbitration with a third author (GJ). The primary author entered
the final data into Review Manager version 5.2.3. Two reviewers (NP and KC) independently
evaluated the methodological rigor of eligible studies using the Cochrane Collaboration’s Risk
of Bias tool [18]. We followed the Grading of Recommendations Assessment, Development, and
Evaluation (GRADE) system [19] to evaluate the strength of evidence (SOE) for patient-centered outcomes across included studies. The overall SOE was graded by two independent
reviewers (NP and LH) with disagreements or uncertainty resolved through discussion and if
necessary, through arbitration with a third author (GJ).

Summary measures and synthesis of results
The primary outcome was the effectiveness of sedation. Due to differences in scales used to
measure sedation, we reported the proportion of participants who’s level of sedation was adequate to facilate the procedure based on the authors’ judgment. If this information wasn’t
available, we reported sedation scores. Secondary outcomes included onset and duration of
sedation, ease of administration, analgesia, additional sedative medication, and adverse effects.
A priori we considered meta-analyses if there was homogeneity in study design, dosing regimen, and indication for sedation. However, due to clinical and methodological heterogeneity
across studies, we conducted a descriptive analysis of each study’s design, population, and primary outcome. When inferential statistics on the primary outcome were not performed, we
analysed raw ordinal data using the Mann-Whitney U statistic (two groups) or the KruskallWallis test (two or more groups). Based on a modification of the classification system of Tricco
et al. [20], we categorized the results of individual studies based on the primary outcome as:
unfavorable (effect in favor of the non-experimental comparator with p value  0.05); neutral
(non-statistically significant difference between interventions with p value > 0.05)); favorable
(effect in favor of the experimental agent with p value  0.05); indeterminate (unable to judge
due to conflicting and multiple primary outcomes). We modified this classification system to
categorize both non-significant positives and negatives as neutral [20].
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Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0173253.g001

Results
Seven studies (264 participants) were included (Fig 1 and S2 Text) [14, 21–26]. Excessive heterogeneity in outcome measures, study design, comparators, dosing, and indications for sedation precluded meta-analysis for any of the studies.

Included studies
The characteristics of included studies can be found in Table 1 and included children undergoing dental procedures (n = 5) [21, 22, 24–26], laceration repair (n = 1) [14], and gastric aspiration (n = 1) [23]. No quasi-randomized trials were eligible. All studies were published in
English as full-text articles. We excluded one study that involved analgesia for children with
fractures that reported sedation-related outcomes because it did not involve a procedure [27].
There was heterogeneity in the frequency and dose of IN ketamine. Single doses ranged from 2
to 10 mg/kg. All studies involved IN ketamine as monotherapy except two that studied IN
ketamine combined with midazolam [23, 24]. The number of arms and comparison interventions were also varied and included benzodiazepines and alternative routes of ketamine delivery. The age of participants ranged from 0 to 14 years.
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Table 1. Characteristics and results of included studies for Procedural Sedation and Analgesia (PSA).
Comparison
Source, trial
Age range
design, country and mean
(context)
age (sample
size)

Measure of effectiveness
of sedation

Results

Summary

Abrams 1993
Parallel group
RCT United
States (dental
procedures)

Range: 17–
62 months;
Mean: NR
(n = 30)

IN Ketamine (3 mg/kg); IN
Sufentanil (1 mcg/kg and
1.5 mcg/kg); IN Midazolam
(0.4 mg/kg)

Depth of sedation (10-item
scale)

Mean sedation score: IN ketamine 4 Neutral
(range 3–6), midazolam 4 (range
2–5), high dose sufentanil 7 (range
2–9), low dose sufentanil 4 (range
3–5) (p = 0.18). Proportions
adequately sedated not reported.

Bahetwar 2011
Crossover RCT
India (dental
procedures)

Range: 2–6
years Mean:
4.6 years
(n = 45)

IN Ketamine (6 mg/kg); IN
Proportion of participants
Midazolam (0.3 mg/kg); IN
with an “adequate”
Midazolam; (0.2 mg/kg) + IN sedation on 1–5 scale
Ketamine (4 mg/kg)

“Adequate” sedation: IN ketamine
42/45 (93%), IN midazolam 38/45
(84%), and IN midazolam + IN
ketamine 40/45 (89%) (p<0.01)

Favorable for IN
ketamine versus IN
midazolam Neutral for
IN ketamine versus IN
midazolam
+ ketamine

Buonsenso 2014
Parallel group
RCT Italy (gastric
aspirates)

Range:
0–14 years
Mean: 41.5
months
(n = 36)

IN Ketamine (2 mg/kg) + IN
Midazolam (0.5 mg/kg);
Placebo (NS)

Depth of sedation using
Modified Objective Pain
Score and proportion
requiring restraint

Mean pain score: IN ketamine + IN
midazolam 3.5; placebo 7.2
(p<0.01). Level of sedation enabled
gastric aspirates without physical
restraint: IN ketamine + IN
midazolam (18/19, 94%) vs.
placebo (0/17, 0%).

Favorable for IN
ketamine
+ midazolam (pain
score and depth of
sedation)

Ghajari 2015
Crossover RCT
Iran (dental
procedures)

Range: 3–6 IN Ketamine (10 mg/kg) + IN
years Mean: Midazolam (0.5 mg/kg); PO
NR (n = 23) Ketamine (10 mg/kg) + PO
Midazolam (0.5 mg/kg)

Sedation measured with
Houpt scale of behavioral
control and proportion with
procedural success

Behavioral control significantly
greater in IN group during
procedure and lidocaine injection
(p<0.05). Procedural success
significantly greater in IN vs. oral
group (97% vs. 39%) and (61% vs.
35%) at 15 and 30 minutes,
respectively (p<0.05). Number of
participants in each group not
reported.

Favorable for IN
versus PO ketamine
+ midazolam
(procedural success)

Pandey 2011
Crossover RCT
India (dental
procedures)

Range: 2–6
years Mean:
4.4 years
(n = 34)

IN Ketamine by nasal
atomizer (6 mg/kg); IN
Ketamine by nasal drops (6
mg/kg)

Proportion with “adequate”
depth of sedation (5-item
scale) and “successful”
sedation (5-item scale)

Adequate depth of sedation with
atomized ketamine (33/34, 97%)
versus drops (31/34, 91%) (ns).
Successful sedation with atomized
ketamine (32/34, 94%) versus
drops (29/34, 85%) (ns).

Neutral

Surendar 2014
Parallel RCT
India (dental
procedures)

Range:
4–14 years
Mean: 7.3
years
(n = 84)

IN Ketamine (5 mg/kg); IN
Midazolam (0.2 mg/kg); IN
Dexmedetomidine (1 mcg/
kg); IN Dexmedetomidine
(1.5 mcg/kg)

Proportion with overall
“satisfactory” sedation
(5-item scale) and
“successful” procedure
(5-item scale)

“Successful” procedure: IN
Neutral
ketamine (14/21, 67%), IN
midazolam (13/21, 62%), IN
dexmedetomidine 1 mcg/kg (17/21,
81%), IN dexmedetomidine 1.5
mcg/kg (18/21, 86%) (ns).
“Satisfactory” sedation: IN ketamine
(16/21, 76%), IN midazolam (15/21,
71%), I dexmedetomidine 1 mcg/kg
(19/21, 91%), IN dexmedetomidine
1.5 mcg/kg (20/21, 95%) (ns).

Tsze 2012
Parallel RCT;
United States
(laceration
repair)

Range: 1–7 IN Ketamine (9 mg/kg); IN
years Mean: Ketamine (6 mg/kg); IN
NR (n = 12) Ketamine (3 mg/kg)

Proportion with “adequate”
depth of sedation using the
Ramsay Sedation Score
(RSS) and the
Observational Scale of
Behavioral DistressRevised

3/3 (100%) patients achieved
“adequate” sedation; all at a dose of
9 mg/kg. Study stopped by data
safety monitoring committee
because there were 9 sedation
failures at doses of 3 mg/kg and 6
mg/kg.

Favorable for IN
ketamine dose of 9
mg/kg vs all other
doses (adequacy of
sedation)

IM intramuscular; IN intranasal; IV intravenous; NR not reported; NS not significant; Observational Scale of Behavioral Distress-Revised; PO per os; PSA
procedural sedation and analgesia; RCT randomized controlled trial; RSS Ramsay Sedation Score; SD standard deviation; VAS visual analog scale
https://doi.org/10.1371/journal.pone.0173253.t001
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Risk of bias within studies
Most studies were judged to have low or unclear risk of bias. Two studies were judged to have
high risk of bias for failing to report pre-specified outcomes [21, 24] (Fig 2).

Risk of bias across studies
Outcome-specific ratings using the GRADE system were low or very low (Table 2). SOE assessments for risk of bias were downgraded primarily due to insufficient information on randomization, allocation concealment (selection bias), or blinding (performance and detection bias).
SOE assessments for consistency were downgraded for all outcomes except analgesia. SOE
assessments for directness were downgraded for all outcomes except analgesia due to the use
of non-validated instruments. SOE assessments for precision were downgraded for all outcomes except adverse effects due to small sample sizes (n < 200).

Onset, duration, and depth of sedation
Depth of sedation was reported in all studies. There was heterogeneity in the time interval
from administration of the intervention to recording this outcome. Two studies [14, 23] used
validated measures of sedation; either the Ramsay Sedation Score (RSS) [28], the Observational
Scale of Behavioral Distress-Revised [29], or the Modified Objective Pain Score [30]. In both
of these studies, the outcome assessor was blinded [14, 23].
Six of seven studies of PSA reported the adequacy of sedation and overall, 148/175 participants (85%) were deemed adequately sedated with IN ketamine to facilitate the procedure [14,
21–23, 25, 26]. Four studies were deemed “favorable” because they reported adequate sedation
in significantly more participants than the comparator [14, 22–24]. They involved IN ketamine
as monotherapy (6 and 9 mg/kg) [14, 22] or co-administered with IN midazolam (0.5 mg/kg)
[23, 24]. Among the two studies that used validated measures of sedation, Tsze et al. found
that only at a dose of 9 mg/kg did IN ketamine produce “adequate” sedation in all three participants undergoing laceration repair [14]. Buonsenso et al. found IN ketamine 2 mg/kg in combination with IN midazolam provided adequate sedation for gastric aspirates (Table 1).
Five studies reported onset of sedation [14, 22, 23, 25, 26], with means ranging from 3.6 to
11.6 minutes. Duration of sedation was reported in all studies and when IN ketamine was used
as monotherapy, the means ranged from 7 to 69 minutes.

Co-administration of IN ketamine with IN midazolam
IN ketamine was co-administered with IN midazolam in two studies [23, 24]. Both provided
“favorable” sedation.

Requirement of additional sedative medication
Provision of additional (rescue) medication for sedation was not reported in any study.

Analgesia
Analgesia was reported in two studies. Surendar et al. included children undergoing dental
extraction [26] and used a validated measure of pain (Faces Legs Activity Cry Consolability
scale [31]). Buonsenso et al. studied children undergoing gastric aspirates [23] also used a validated measure (Modified Objective Pain Score [32]). Both studies found IN ketamine to provide adequate analgesia.
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Fig 2. Risk of bias summary based on judgements about each item for each included study. Low risk of bias,
Unclear risk of bias, High risk of bias.
https://doi.org/10.1371/journal.pone.0173253.g002
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Table 2. Strength of Evidence (SOE) assessments based on (Grading of Recommendations Assessment, Development, and Evaluation) GRADE
system.
Outcome

Number of
trials Number Risk of
of participants bias
Instrument(s)
Citation
number

Quality assessmenta
Consistency
(of effects
between
studies)

Directness
(generalizability
to population of
interest)

Precision Other
considerations

Importance Strength
of
evidenceb

Depth of sedation or proportion adequately sedated
IN ketamine vs IN midazolam
vs IN ketamine + IN
midazolam combination
(Bahetwar 2011)

1; 45; Nonvalidated 4
item scales

Seriousc

Unknownd

Some uncertainty
about directnesse

Imprecise None

Criticalf

Low

IN ketamine + IN midazolam
combination vs IN saline
(Buonsenso 2014)

1; 36; MOPS

None

Unknownd

Direct

Imprecise None

Criticalf

Lowg

IN ketamine + IN midazolam
combination vs PO ketamine
+ PO midazolam combination
(Ghajari 2015)

1; 23; Nonvalidated
behavioral
scale

Serioush

Unknownd

Some uncertainty
about directnesse

Imprecise High probability Criticalf
of reporting biasi

IN ketamine vs IN ketamine
(varying dose or routes)
(Tsze 2012; Pandey 2011)

2; 46; Nonvalidated
5-item scale;
RSS; OSBD-R

Seriousc

Inconsistent

Some uncertainty
about directnesse

Precise

None

Criticalf

Low

IN ketamine vs IN opioid
(sufentanil) vs IN midazolam
(Abrams 1993)

1; 30; Nonvalidated
10-item scale

Seriousc

Unknownd

Some uncertainty
about directnesse

Precise

High probability Criticalf
of reporting biasi

Low

IN ketamine vs IN
dexmedetomidine vs IN
midazolam (Surendar 2014)

1; 84; Nonvalidated
5-item scale

Seriousc

Unknownd

Some uncertainty
about directnesse

Precise

None

Criticalf

Lowg

IN ketamine alone vs
comparators (Bahetwar 2011;
Surendar 2014; Pandey
2011; Tsze 2012)

4; 175; RSS;
OSBD-R Nonvalidated 3 to
5-item scales

Seriousc

Inconsistentn

Some uncertainty
about directnessk

Precise

None

Less
important

Low

IN ketamine + IN midazolam
combination vs comparators
(Buonsenso 2014)

1; 36; MOPS

Seriousc

Unknownd

Some uncertainty
about directnessk

Imprecise None

Less
important

Low

IN ketamine alone vs
comparators (Abrams 1993;
Bahetwar 2011; Pandey
2011; Surendar 2014; Tsze
2012)

5; 205; RSS;
OSBD-R Nonvalidated 4, 5,
and 10-item
scales

Seriousc,j Inconsistentl

Some uncertainty
about directnessk

Precise

None

Importantm

Low

IN ketamine + IN midazolam
combination vs comparators
(Buonsenso 2014; Ghajari
2015)

2; 59; MOPS;
Non-validated
behavioral
scale

Seriousc

Inconsistentl

Some uncertainty
about directnessk

Imprecise None

Importantm

Very low

2; 120;
FLACC;
MOPS

Seriousc

Consistent

Direct

Imprecise None

Less
important

Low

Mucosal atomizer device
(Pandey 2011)

1; 34; Nonvalidated
5-item scale

Seriousc

Unknownd

Some uncertainty
about directnessk

Imprecise None

Importantn

Low

Not specified (Bahetwar
2011; Ghajari 2015)

2; 68; Not
specified

Seriousc

Inconsistent

Some uncertainty
about directnessk

Precise

Importantn

Low

Very low

Onset of sedation

Duration of sedation

Analgesia
IN ketamine or IN ketamine
+ IN combination midazolam
vs comparators (Buonsenso
2014; Surendar 2014)
Ease of administration

None

(Continued)
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Table 2. (Continued)
Outcome

Number of
trials Number Risk of
of participants bias
Instrument(s)
Citation
number

Quality assessmenta
Consistency
(of effects
between
studies)

Directness
(generalizability
to population of
interest)

Precision Other
considerations

Importance Strength
of
evidenceb

Adverse effects
IN ketamine alone vs
comparators (Abrams 1993;
Bahetwar 2011; Pandey
2011; Tsze 2012)

4; 121;
Frequencies

Seriousc

Inconsistent

Some uncertainty
about directnessp

Precise

None

Criticalo

Low

IN ketamine + IN midazolam
combination vs comparators
(Buonsenso 2014; Ghajari
2015)

2; 59;
Incidence

Seriousc

Inconsistent

Some uncertainty
about directnessp

Precise

None

Criticalo

Low

FLACC Faces Legs Arms Cry Consolability; IN intranasal; MOPS Modified Objective Pain Score; OSBD-R Observational Scale of Behavioral DistressRevised; RSS Ramsay Sedation Score; VAS Visual Analog Scale;
a
Decrease score for: Risk of Bias -serious (-1) or very serious (-2) limitation to study quality; Consistency—important inconsistency of effects between
studies (-1); Directness—some (-1) or major (-2) concerns about generalizability to population of interest; Precision–imprecise or sparse data based on
number of outcome events or sample size < 200 (-1); Other Considerations–high probability of reporting bias (-1)
SOE assessments were made using the GRADE approach as follows: Start at high, downgrade to medium due to risk of bias, downgrade to low due to

b

imprecision, downgrade to very low due to other considerations such as risk of reporting bias. SOE categorizations are high quality: further research is very
unlikely to change our confidence in the estimate of effect; moderate quality: further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate; low quality: Further research is very likely to have an important impact on our confidence in the estimate of
effect and is likely to change the estimate; very low quality: Any estimate of effect is very uncertain
c

Most or all studies report insufficient details of at  1 of: randomization, allocation concealment (selection bias), or blinding (performance and detection
bias)

d

Unable to assess given only one study

e

Use of a non-standardized tool to determine level and adequacy of sedation in at least one study limits the degree to which the results can be applied
broadly

f

This outcome was deemed critical because suboptimal sedation leads to pain and distress and can lengthen the duration of procedural sedation, increasing

the risk of morbidity
g
Downgraded because only a single study contributed to the comparisons
h

Method of randomization and allocation concealment not reported (selection bias); participant numbers not reported; not all outcomes reported (reporting

bias)
i
Authors did not report all pre-specified outcomes (reporting bias)
j

At least one study in which complete follow-up of participants was not specified (attrition bias)

k

Use of a non-standardized tools to measure this outcome limits the degree to which the results can be applied broadly
Downgraded for consistency due to the large range in this outcome, which was in turn likely due to heterogeneity in measurement instruments and dose

l

m

This outcome was deemed important (rather than critical) because it is a determinant of the expected duration of monitoring. While it may not affect

morbidity and mortality, it may impact staffing resources, making it important to health care providers
n
This outcome was deemed important (rather than critical) because although it may not affect morbidity and mortality, the willingness of a patient to accept
IN therapy may impact staffing resources and the willingness of the clinician to use it
o

This outcome was deemed critical because although adverse effects were generally minor and transient, they may affect morbidity and mortality
Validated tools not consistently used to ascertain or quantify emergence agitation

p

https://doi.org/10.1371/journal.pone.0173253.t002

Ease of IN administration
Three studies reported administration with a mucosal atomizer device (MAD) [14, 23, 25].
The remainder described only a “syringe” or provided no description. Ease of IN ketamine
administration was reported in three studies [22, 24, 25] but the proportion of participants in
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which administration was well tolerated (71/79, 90%) was reported in only two studies
[22, 25]. Pandey et al. reported IN ketamine was significantly better tolerated than ketamine
drops using a standardized tool for behavioral response in 34 participants [25].

Adverse effects
Adverse effects were reported in six studies [14, 21–25]. This was most commonly nausea and
vomiting and reported in four studies [14, 22, 24, 25]. Only Buonsenso et al. reported emergence agitation [23] and did not use a validated scale to measure it’s degree. Overall, vomiting
and emergence agitation was reported in 9/91 (10%) and 6/57 (11%) participants who received
IN ketamine, respectively, either alone or in combination with midazolam. Abrams et al. was
the only study to report transient, spontaneously-resolving oxygen desaturations in two of ten
participants [21].

Discussion
This systematic review assessed the effectiveness of IN ketamine for sedation across all randomized trials of children undergoing PSA. IN ketamine administration was generally well tolerated with minor adverse effects. Although most participants were deemed adequately
sedated, superiority of IN ketamine over comparators with respect to effective sedation was
inconsistent. Most studies had a low or unclear risk of bias and the quality of evidence was low
or very low. At present, there is insufficient evidence to recommend IN ketamine for PSA in
children in clinical settings.
One of our primary objectives was to review the evidence for IN ketamine in PSA. Although
most participants achieved adequate sedation, studies were inconsistent for sedation effectiveness versus comparators. This may have been due to heterogeneity in dosing, non-experimental comparators, scales, and indications. Only Tzse et al. used a validated tool and a blinded
outcome assessor to measure sedation [14]. Despite the study’s small sample size, their findings
suggest that 9 mg/kg is required for effective sedation for laceration repair. Importantly, there
were no trials exploring IN ketamine for fracture reduction, the most common pediatric indication for PSA [33, 34]. There were also no trials comparing IN ketamine to IV sedatives, making it difficult to ascertain whether the level of sedation produced by IN ketamine can obviate
the need for an IV. As such, no recommendations can be made for IN ketamine in PSA in
children.
The need for additional (rescue) sedative medication was not described in any reviewed
study. For clinicians, this outcome is important because rescue sedation, most likely administered through an IV, would offset the benefits of IN administration. Therefore, the need for
rescue sedation should be included as an outcome in future trials of sedation effectiveness.
Wide ranges were found in reporting onset and duration of sedation, likely owing to varied
instruments and definitions of this interval. Onset of sedation in studies reporting this outcome was appreciably longer (11 minutes) than what has been described for IV ketamine (1
minute) [35]. This is consistent with IN ketamine’s time to peak plasma concentration of 18
[36] to 21 minutes [37]. Duration of sedation is an outcome important to patients, administrators and clinicians. Yet, only one study used a validated measure of sedation and a blinded outcome assessor. The authors reported a range of 42 to 69 minutes with a dose of 9 mg/kg [14].
This data was obtained from only three participants and future investigations of IN ketamine
must report this clinically relevant outcome.
The co-administration of benzodiazepines with ketamine has been traditionally recommended as a strategy to mitigate emergence reactions [38]. In contrast to adults [39], a large
meta-analysis has not supported a role for midazolam in reducing emergence reactions in
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children [40]. Consistent with this, only one study in our review reported emergence agitation
in children receiving IN ketamine co-administered with IN midazolam. The authors reported
a greater incidence of emergency agitation (6/57, 11%) [23] than previously described (1.5%)
[40]. Despite their study’s methodological limitations, Bahetwar et al. compared IN ketamine
co-administered with IN midazolam to each intervention alone [22] and their findings suggested that the addition of IN midazolam to IN ketamine confers no benefit to depth of sedation. Co-administration of a benzodiazepine has been identified as a risk factor for airway
complications in children [41] and adults [42]. As such, the co-administration of IN ketamine
and IN midazolam cannot be recommended for PSA in children.
Our review found that despite higher per kilogram doses of IN ketamine, the incidence of
the most frequent adverse effect, vomiting, was consistent with a previous report [40]. This
was not unexpected given that there is no evidence of a dose relationship with IV ketamine
[40]. Importantly however, the frequency of emergence agitation in our review [23] was more
than three-fold greater than previously reported for IV ketamine [40]. The data from our
review must be interpreted with caution however, as Buonsenso et al. reported cases of emergence agitation in children undergoing gastric aspirates [23] using a non-standardized definition of this outcome. Future trial designs should utilize validated measures to describe
emergence agitation and its clinical significance. The lack of serious adverse events in our
review is consistent with Green et al.’s meta-analysis of IV ketamine in children where the
authors found serious, albeit transient complications (laryngospasm and apnea), in 0.3% and
0.8%, respectively [41]. The number of participants in our review was insufficient to detect
these serious outcomes. Patient safety is quite likely the most important variable for health
care providers considering the use of IN ketamine over the IV route. Given the relative infrequency of these potentially serious complications, long-term surveillance studies may be the
best approach to accurately estimate this risk.
Only three studies reported that interventions were in fact atomized [14, 23, 25]. Fluid volumes in excess of 0.3 mL that are instilled into the nasopharynx without an MAD may result
in excess drug deposition into the pharynx [43]. Although a non-atomized approach has been
described [3], it may result in unpredictable drug deposition, raising the possibility that sedative effects may be due to oral rather than transmucosal absorption.
Analgesia was not the primary focus of our review. However, this parameter is a salient feature of an ideal monotherapy for PSA [44]. Buonsenso et al. [23] reported that IN ketamine
was associated with a reduction in pain scores that exceeded the minimal clinically important
difference on the Modified Objective Pain Score [30]. Surendar et al. reported similar findings
but the clinical significance of the analgesic effect was uncertain and change scores were not
reported [26]. Although limited, evidence from this review pertaining to analgesia was consistent and is in line with what is known about ketamine’s analgesic properties [45]. Consistency
in analgesic efficacy across studies using validated instruments suggests that IN ketamine can
be recommended as an effective analgesic for the indications reviewed. A notable caveat is that
our search did not include all studies reporting analgesia. As a result, specific recommendations for indications and dosing regimen are beyond the scope of this review.

Limitations
The primary limitation of our review was our decision to summarize results based on the
authors’ judgement of the adequacy of sedation. This measure was inherently subjective, given
the lack of a consistent, objective definition of adequacy, even among studies using validated
instruments. The Canadian Anesthesiologists’ Society has recommended the use of instruments with identifiable endpoints such as the RSS [44], used in several reviewed studies.
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However, a blinded outcome assessor, remote from the clinical encounter, and a tool that does
not involve physically stimulating the participant, such as the Dartmouth Operative Conditions Scale [46], would provide a more non-intrusive and therefore objective way to measure
sedation.

Conclusions
In this systematic review of seven studies, IN ketamine produced sedation adequate enough to
perform the procedure under study. However, the superiority of IN ketamine over comparators with respect to effective sedation was inconsistent. IN ketamine was well tolerated in most
participants without serious adverse effects. Reviewed studies were limited by poor methodological rigor, small sample sizes, inconsistent results, and limited generalizability with respect
to effectiveness of sedation. These factors preclude a recommendation for the use of IN ketamine for PSA in children in clinical settings. No study explored the utility of IN ketamine for
common procedures such as fracture reduction or compared IN ketamine to IV sedatives. The
adoption of IN over IV ketamine by clinicians is therefore contingent on the findings of larger,
high quality trials that employ validated instruments and are adequately powered to detect
clinically meaningful differences in outcomes such as analgesia, depth and duration of
sedation.

Supporting information
S1 Text.
(PDF)
S2 Text.
(PDF)
S3 Text.
(PDF)
S4 Text.
(PDF)

Author Contributions
Conceptualization: NP KC AS GJ MR.
Data curation: NP SA LH.
Formal analysis: NP MM LH.
Investigation: NP KC LH.
Methodology: AS GJ LH.
Project administration: MR LH.
Resources: SH KC LH.
Software: SH NP.
Supervision: MR LH.
Writing – original draft: NP KC SA LH.
Writing – review & editing: NP KC GJ AS MR SA LH SH MM.

PLOS ONE | https://doi.org/10.1371/journal.pone.0173253 March 20, 2017

12 / 15

Intranasal ketamine for procedural sedation and analgesia in children

References
1.

Nelson R. Decade of pain control and research gets into gear in USA. The Lancet. 2003; 362
(9390):1129.

2.

Correll DJ, Vlassakov KV, Kissin I. No evidence of real progress in treatment of acute pain, 1993–2012:
scientometric analysis. Journal of pain research. 2014; 7:199–210. https://doi.org/10.2147/JPR.S60842
PMID: 24748816

3.

Del Pizzo J, Callahan JM. Intranasal Medications in Pediatric Emergency Medicine. Pediatric Emergency Care. 2014; 30(7):496–501. https://doi.org/10.1097/PEC.0000000000000171 PMID: 24987995

4.

Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesthesia and Analgesia. 2007; 105(1):205–21. https://doi.org/10.1213/01.ane.0000268145.52345.55 PMID: 17578977

5.

Fein JA, Zempsky WT, Cravero JP, et al. Relief of pain and anxiety in pediatric patients in emergency
medical systems. Pediatrics. 2012; 130(5):e1391–405. https://doi.org/10.1542/peds.2012-2536 PMID:
23109683

6.

Wong DL, Baker CM. Pain in children: Comparison of assessment scales. Journal of Pediatric Nursing.
1988; 14(1):9–17.

7.

Fradet C, McGrath PJ, Kay J, Adams S, Luke B. A prospective survey of reactions to blood tests by children and adolescents. Pain. 1990; 40(1):53–60. PMID: 2339016

8.

Goodenough B, Thomas W, Champion GD, Perrott D, Taplin JE, von Baeyer CL, et al. Unravelling age
effects and sex differences in needle pain: ratings of sensory intensity and unpleasantness of venipuncture pain by children and their parents. Pain. 1999; 80(1):179–90.

9.

Humphrey GB, Boon CM, van den Heuvell GFE, van de Wiel C. The occurrence of high levels of acute
behavioral distress in children and adolescents undergoing routine venipunctures. Pediatrics. 1992; 90
(1 Pt 1):87–91. PMID: 1614786

10.

Van Cleve L, Johnson L, Pothier P. Pain responses of hospitalized infants and children to venipuncture
and intravenous cannulation. Journal of Pediatric Nursing. 1996; 11(3):161–8. https://doi.org/10.1016/
S0882-5963(96)80049-2 PMID: 8667153

11.

Couloures KG, Beach M, Cravero JP, Monroe KK, Hertzog JH. Impact of provider specialty on pediatric
procedural sedation complication rates. Pediatrics. 2011; 127(5):e1154–e60. https://doi.org/10.1542/
peds.2010-2960 PMID: 21518718

12.

Schofield S, Schutz J, Babl FE. Procedural sedation and analgesia for reduction of distal forearm fractures in the paediatric emergency department: a clinical survey. EMA. 2013; 25(3):241–7. https://doi.
org/10.1111/1742-6723.12074 PMID: 23759045

13.

Murphy AP, Hughes M, McCoy S, Crispino G, Wakai A, O’Sullivan R. Intranasal fentanyl for the prehospital management of acute pain in children. European Journal of Emergency Medicine. 2016 Mar 15
[Epub ahead of print]

14.

Tsze DS, Steele DW, Machan JT, Akhlaghi F, Linakis JG. Intranasal ketamine for procedural sedation
in pediatric laceration repair: a preliminary report. Pediatric Emergency Care. 2012; 28(8):767–70.
https://doi.org/10.1097/PEC.0b013e3182624935 PMID: 22858745

15.

Andolfatto G, Willman E, Joo D, Miller P, Wong W-B, Koehn M, et al. Intranasal ketamine for analgesia
in the emergency department: a prospective observational series. Academic emergency medicine.
2013; 20(10):1050–4. https://doi.org/10.1111/acem.12229 PMID: 24127709

16.

Ibrahim M. A prospective, randomized, double blinded comparison of intranasal dexmedetomodine vs
intranasal ketamine in combination with intravenous midazolam for procedural sedation in school aged
children undergoing MRI. Anesthesia, Essays and Researches. 2014; 8(2):179–86. https://doi.org/10.
4103/0259-1162.134495 PMID: 25886223

17.

Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of the Endorsement of the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses. PLOS ONE. 2013; 8(12):e83138. https://doi.org/10.
1371/journal.pone.0083138 PMID: 24386151

18.
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